会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 30. 发明申请
    • METHODS OF TREATING AUTOIMMUNE DISEASES USING IL-17 ANTAGONISTS
    • 使用IL-17拮抗剂治疗自身免疫性疾病的方法
    • WO2014155278A3
    • 2014-12-18
    • PCT/IB2014060110
    • 2014-03-24
    • NOVARTIS AGBRACHAT ARNDT HOLGERWANG YING
    • BRACHAT ARNDT HOLGERWANG YING
    • G01N33/50
    • C12Q1/6883A61K2039/505C07K16/244C07K2317/21C07K2317/76C07K2317/90C12Q2600/106C12Q2600/156G01N33/564G01N2333/948G01N2800/52
    • The disclosure is directed to novel predictive methods and personalized therapies for treating an autoimmune disease (AI) selected from psoriasis, uveitis, rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and multiple sclerosis (MS). Specifically, this disclosure relates to methods of treating a patient having an AI disease by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having uveitis, RA, PsA, AS, psoriasis or MS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.
    • 本公开涉及用于治疗选自牛皮癣,葡萄膜炎,类风湿性关节炎(RA),银屑病关节炎(PsA),强直性脊柱炎(AS)和多发性硬化症(MS))的自身免疫性疾病(AI)的新型预测方法和个性化疗法。 具体而言,本公开涉及通过基于该遗传易感患者具有IL-17拮抗剂(例如,IL-17抗体,例如塞沙单抗)来治疗患有AI疾病的患者的方法,所述IL-17拮抗剂 对IL-17拮抗剂治疗的有利反应。 本文还公开了可用于预测患有葡萄膜炎,RA,PsA,AS,银屑病或MS对患有IL-17拮抗剂(例如IL-17)的治疗有反应的患者的信息,诊断方法和试剂盒的可传输形式, 17抗体,如secukinumab。